A study posted in JAMA Network Open up emphasizes the discrepancy in between what it prices to provide copyright as well as retail prices sufferers experience. Despite the reduced output costs, Novo Nordisk hasn't publicly disclosed unique figures for copyright or its other solution, Wegovy.